Drug intelligence / Profile preview

T3P-Y098

Development stage: Preclinical
Lead developer: Boehringer Ingelheim
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics
Administration: Intratumoral, Intravenous

Overview

T3P-Y098 is an investigational drug candidate developed by T3 Pharmaceuticals AG. It is currently in preclinical development for the treatment of neoplasms (cancers). While detailed mechanistic information specific to T3P-Y098 is not available, it belongs to a pipeline of agents from T3 Pharmaceuticals that utilize recombinant live bacterial products (LBPs) as a modality, with other related candidates targeting immune modulation in cancer. The primary indication under investigation for T3P-Y098 is neoplasms[1][2].

Beyond the preview

Go deeper on T3P-Y098.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T3P-Y098.

Explore the full profile